The concurrent use of N-and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients The delocalisation of the nucleophosmin 1 (NPM1) nucleolar protein to the cytoplasm, denoted as NPMc þ , arises as a consequence of genetic mutations that modify the protein's C-terminus introducing a nuclear export signal and abolishing a nucleolar localisation signal. 1 The mutations of NPM1 are found in approximately 30% of cases of acute myeloid leukaemia (AML), 2 however, despite their clinical relevance, there are only a few reagents (Table 1) suitable for diagnostic  applications and research. 3 The NA24, 322 and 376 (refs 2, 4) monoclonal antibodies recognise the N-terminus of both wild-type (wt) NPM1 and NPMc þ and have been used extensively in immunohistochemistry and immunofluorescence to identify the cytoplasmic displacement of the NPM mutant, 2, 5, 6 whereas the SilA and SilC rabbit polyclonal antibodies that specifically recognise the mutated C-terminal region have Letters to the Editor been used in western blotting and immunoprecipitation. 5, 7, 8 Successful flow cytometric detection of NPM1 mutants has been obtained using the 5E3 monoclonal antibody. 3 Recently, T26, a monoclonal antibody specifically directed against the de novo sequence present in most of the NPMc þ mutants has been generated and shown as being potentially efficient in different immunotechniques used for the diagnostic work up of the disease. 9 The mutations in the NPM1 locus encountered in AML are always heterozygous, and thus in the NPMc þ AML blasts, wt NPM and NPMc þ co-exist. However, the two proteins show a different subcellular localisation, with the wt protein present predominantly in the nucleoli and the mutant dispersed in the cytoplasm. The situation is complicated by the fact that NPM1 protein forms oligomers, and given that the domains of oligomerisation are retained in the various mutants, heterooligomers consisting of wt NPM1 and NPMc þ occur as well. In this way, the wt protein is taken out of nucleolus by the mutant that exerts a dominant-negative effect over the wt protein as observed by Colombo et al. 10 Similarly, Bolli et al. 11 observed that in transfected cells, excess doses of NPMc þ relocate completely wt NPM1 from the nucleoli to the cytoplasm, a distribution pattern seen also in a proportion of NPMc þ AML patients. The excess of NPM1wt in transfected cells, on the other hand, relocated NPMc þ from the cytoplasm to the nucleoli. Notably, this distribution pattern is extremely rare in patients' samples, although it has been described in small percent of cells in some of the cases tested with the use of the T26 antibody by immunofluorescence. 9 The reliability of detecting the cytoplasmic localisation of NPM1 as a surrogate marker for the presence of the mutations in diagnostic settings has recently been questioned by Konoplev et al. 12 and Mattsson et al. 13 As these groups have used 376 and NA24 antibodies previously validated and successfully used by other researchers, 5, 6 it appears that the results may be strongly influenced by technicalities related to sample preparation and fixation. Furthermore, data published to date originate from single-colour staining experiments as all of the antibodies available that work well in immunofluorescence are of murine origin, thus making it difficult to design co-staining experiments, necessary for obtaining contemporaneously a precise picture of wt NPM1 and NPMc þ distribution. To address this issue, we have used a naive VHH antibody phage display library 14 in order to rapidly generate anti-NPM1 recombinant antibodies. A selected binder (23H) that recognises a N-terminal epitope (amino acids 1-117) within NPM1 has been cloned into modified expression vectors to obtain the VHH domain of interest fused to a rabbit Fc as previously published 15 (Supplementary Figure 1) . The combination of the T26 murine antibody raised against the de novo sequence, specific for the NPMc þ exclusively, 9 and of the rabbit Fc-VHH that recognises both NPM1 forms present in the cell enabled us to perform the first dual-colour staining experiment reported so far on both cell lines and patients' samples ( Figure 1 ). The staining was performed using standard protocols on cells fixed in 4% paraformaldehyde as described before. 9 We confirm here that a co-staining of cells deriving from the mutant-bearing OCI-AML3 cell line and of patients' blasts allowed us to observe the presence of the mutant in the cytoplasm and of the wt protein in the nucleolus as shown in Figure 1 . The pattern of staining was consistent with a prevalently cytoplasmic localisation of the mutant-specific T26 antibody in the OCI-AML3 cells and in bone marrow smears of primary patients' material, whereas the signal of the 23H antibody had a dual nucleolar and cytoplasmic pattern. Moreover, the nucleolar staining of the 23H antibody seems more robust than the staining obtained with previously published murine antibodies as we have never seen any cytoplasmic diffusion in patients without a mutation, formerly reported by Konoplev et al. 12 and Mattson et al. 13 To this point, the false cytoplasmic localisation of the murine 322 in the OCI-AML2 cells and of the 376 antibody's signal in the lower panel of the two wt NPM1 AML patients has been otherwise not seen with the 23H antibody. Finally, the novel antibody reported here may be of use as a research tool on samples deriving from transgenic mice generated in order to study the NPMc þ driven processes of leukaemogenesis.
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The authors declare no conflict of interest. Imatinib induces rapid and durable complete hematologic and molecular remissions in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Primary resistance has not yet been reported and secondary resistance seems to be rather rare. In a German-wide registry, we currently oversee the clinical course of 57 patients who have been treated with imatinib for a median of 36 months (range 1-82) at doses ranging between 100 mg every other day and 400 mg/day. Recently, we identified the first case of secondary resistance in a 50-year-old male patient, 7 months after imatinib 400 mg/day was started. The patient presented in hematologic relapse with leukocytosis (37 Â 10 9 /l, 71% eosinophils), anemia (Hb 9.8 g/dl), thrombocytopenia (37 Â 10 9 /l) and splenomegaly. The karyotype was normal, but reverse transcription-PCR with primers covering the juxtamembrane and tyrosine kinase domains of platelet-derived growth factor receptor A (PDGFRA) (exons 11-18) and subsequent sequence analysis identified a C4T change that predicts a T674I mutation in the ATP-binding region of PDGFRA (PDGFRA   T674I   ) . Including the case presented here, seven cases of secondary resistance to imatinib have now been reported in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. [1] [2] [3] [4] [5] [6] [7] We analyzed the clinical and molecular characteristics from four patients with a T674I mutation, 1, 3, 5, 7 one patient with a D842V mutation 6 and one patient with a T674I mutation, followed by a D842V mutation (Table 1) . 4 All patients were male, the median age at diagnosis was 39 years (range 25-67). Imatinib had been administered at doses of 100 mg every other day (1/5), 100 mg/day (2/5) or 400 mg/day (2/5); in two cases, the dose of imatinib had been not reported. The median time to imatinib resistance was 5 months (range 2-9). Marrow blasts were increased in five of seven patients, suggesting accelerated/blast phase. Four patients died, three of them within 5 months after diagnosis of secondary resistance to imatinib (time interval was not reported in the fourth patient). 3, 4, 6, 7 The cases above indicate that secondary resistance is rare, but it is also notable that only two different mutations (T674I, D842V) have yet been identified. towards second-generation tyrosine kinase inhibitors, we treated our patient with nilotinib 400 mg twice a day. However, no response was observed within 4 weeks of treatment and in fact, eosinophil numbers increased. We therefore switched to sorafenib 400 mg twice a day. Similar to nilotinib, there were no signs of response within 2 months of treatment (stable disease). Of interest, a second patient treated with sorafenib only showed a short-lived clinical response (3 months) due to the rapid emergence of a D842V mutant. 4 Meanwhile, a brother of our patient was identified as a fully HLA-identical sibling stem cell donor. Allogeneic stem cell transplantation was performed 5 months after first detection of imatinib-resistance. The conditioning regimen was a modified FLAMSA-RIC protocol, consisting of fludarabine 30 mg/m 2 , high-dose cytarabine 2 g/m 2 , and amsacrine 100 mg/m 2 from days À14 to À11, busulvex 3.2 mg from days À7 to À5, and anti-thymocyte globin (ATG) total 30 mg/kg fractionated from day À4 to À1. Posttransplant, he developed steroid-responsive grade II graftversus-host-disease of the skin and subsequently limited chronic graft-versus-host-disease. Complete hematopoietic chimerism was achieved 4 months after transplant. At the time of reporting ( þ 392 days), the patient is well and in complete hematologic and molecular remission.
Nilotinib, sorafenib and midostaurin demonstrated excellent activity at nanomolar concentrations towards PDGFRA T674I in cell lines, transfected cells and in mouse models. The lack of clinical activity of two of these drugs in a patient with PDGFRA T674I raises concerns regarding (i) additional molecular abnormalities conferring resistance independent of the underlying point mutation or (ii) other unknown factors that are contributing to potentially misleading results from in vitro studies. In this respect, it should be noted that the situation is similar to the KIT D816V mutation in patients with systemic mastocytosis. Nilotinib, dasatinib and midostaurin have been shown to suppress the malignant clone in cells and mice at therapeutic concentrations. However, only midostaurin, but not nilotinib or dasatinib, have yet shown adequate clinical activity. The activity regarding hematological and molecular remissions of Janus kinase inhibitors in JAK2 V617F positive myeloproliferative neoplasms is also clearly inferior to what we would have expected from in vitro experiments.
